Table 1 Baseline characteristics of the AL amyloidosis patients and healthy controls

 Male/female

52/30

10/10

0.27

 Age (years)

55.5 ± 8.5

53.2 ± 11.7

0.30

 NYHA (I/II/III/IV)

30/24/23/5

–

–

 cTnI (μg/L)

0.043 (0.015–0.146)

0.000 (0.000–0.040)

0.024

 NT-proBNP (pg/mL)

2056 (348–6096)

0 (0–23)

0.001

 dFLC (mg/L)

138.0 (46.0–391.5)

–

–

 Mayo Stage (I/II/III/IV)

22/18/29/13

–

–

 Creatinine (umol/L)

87.3 ± 21.6

74.9 ± 15.3

0.21

 HTN/CHD/DM/Af

16/6/3/2

–

–

 Therapy (BCD/TCD/ASCT)

5/4/2

–

–

 E/A

1.3 ± 0.7

–

–

 E/E’

16.8 ± 8.3

–

–

 Indexed LVEDV (ml/m²)

58.3 ± 16.0

74.5 ± 17.1

0.001

 Indexed LVESV (ml/m²)

22.1 ± 12.4

21.5 ± 8.1

0.79

 LVEF (%)

63.3 ± 14.6

70.3 ± 8.7

0.043

 Left atrium area (cm²)

21.4 ± 5.0

20.6 ± 5.0

0.52

 Indexed left ventricle mass (g/m²)

93.5 ± 29.0

65.2 ± 15.3

0.001

 Septal thickness (mm)

15.4 ± 4.0

10.5 ± 2.0

0.001

 LGE (no/patchy/global)

26/18/38

–

–

 Native T1 (ms)

1438 ± 120

1283 ± 46

0.001

 ECV (%)

43.9 ± 10.9

27.0 ± 1.7

0.001